Plasma-derived therapeutics start from human blood plasma instead of the chemical or synthetic materials from which most pharmaceuticals are made.
This report contains market size and forecasts of Plasma-derived Therapies in Global, including the following market information:
Global Plasma-derived Therapies Market Size 2024-2030, ($ millions)
The global Plasma-derived Therapies market is projected to reach US$ million by 2029.
We surveyed the Plasma-derived Therapies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Plasma-derived Therapies Market, by Type, 2024-2030 ($ millions)
Global Plasma-derived Therapies Market Segment Percentages, by Type
Albumin
Immunoglobulin
Factor VIII
Others
Global Plasma-derived Therapies Market, by Application, 2024-2030 ($ millions)
Global Plasma-derived Therapies Market Segment Percentages, by Application
Hemophilia
Primary Immunodeficiencies (PIDs)
Idiopathic Thrombocytopenic Purpura (ITP)
COVID-19
Others
Global Plasma-derived Therapies Market, By Region and Country, 2024-2030 ($ Millions)
Global Plasma-derived Therapies Market Segment Percentages, by region and country
United States
Europe
Asia
China
Rest of World
Competitor Analysis
The report also provides analysis of leading market participants including:
Further, the report presents profiles of competitors in the market, key players include:
CSL Behring LLC
Shire
Bayer
Kedrion
Takeda
Biotest
Octaparma
Bio Products Laboratory (BPL)
LFB
Grifols
